Clinical significance of the CCR5delta32 allele in hepatitis C

Isabelle Morard, Sophie Clément, Alexandra Calmy, Alessandra Mangia, Andrea Cerny, Andrea De Gottardi, Meri Gorgievski, Markus Heim, Raffaele Malinverni, Darius Moradpour, Beat MúLllhaupt, David Semela, Stéphanie Pascarella, Pierre Yves Bochud, Franco Negro

Research output: Contribution to journalArticlepeer-review


Background: The CCR5 receptor, expressed on Th1 cells, may influence clinical outcomes of HCV infection. We explored a possible link between a CCR5 32-base deletion (CCR5delta32), resulting in the expression of a non-functioning receptor, and clinical outcomes of HCV infection. Methods: CCR5 and HCV-related phenotypes were analysed in 1,290 chronically infected patients and 160 patients with spontaneous clearance. Results: Carriage of the CCR5delta32 allele was observed in 11% of spontaneous clearers compared to 17% of chronically infected patients (OR = 0.59, 95% CI interval 0.35-0.99, P = 0.047). Carriage of this allele also tended to be observed more frequently among patients with liver inflammation (19%) compared to those without inflammation (15%, OR = 1.38, 95% CI interval 0.99-1.95, P = 0.06). The CCR5delta32 was not associated with sustained virological response (P = 0.6), fibrosis stage (P = 0.8), or fibrosis progression rate (P = 0.4). Conclusions: The CCR5delta32 allele appears to be associated with a decreased rate of spontaneous HCV eradication, but not with hepatitis progression or response to antiviral therapy.

Original languageEnglish
Article numbere106424
JournalPLoS One
Issue number9
Publication statusPublished - Sep 5 2014

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Clinical significance of the CCR5delta32 allele in hepatitis C'. Together they form a unique fingerprint.

Cite this